ArticlePsychopharmacology2026
Nucleus accumbens CD81 regulates methamphetamine-induced locomotor activity, conditioned reward, and reinstatement in male and female rats.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundMethamphetamine (METH) use disorder is characterized by high rates of relapse and persistent neurobehavioral alterations. CD81, a member of the tetraspanin family, has been implicated in synaptic plasticity and addiction-related behaviors, but its role in METH-induced behavioral adaptations remains unknown.
aimsTo determine whether METH-induced conditioned reward is associated with alterations in endogenous nucleus accumbens (NAcc) CD81 expression and to examine the effects of viral-mediated CD81 overexpression on METH-induced behavioral responses.
methodsMale and female rats underwent METH-induced conditioned place preference (CPP), after which endogenous CD81 mRNA expression was quantified in the NAcc. Based on these findings, separate cohorts received bilateral intra-accumbal injections of either control or CD81-expressing lentiviral vectors. The effects of CD81 overexpression on acute METH-induced locomotor activity, CPP acquisition, and METH-primed reinstatement following extinction were subsequently evaluated.
resultsMETH-conditioned animals exhibited significantly reduced accumbal CD81 mRNA expression, and endogenous CD81 levels were negatively correlated with CPP acquisition. Viral-mediated CD81 overexpression significantly attenuated METH-induced locomotor activation, reduced CPP acquisition, and suppressed METH-primed reinstatement following extinction. Accumbal CD81 mRNA expression was negatively correlated with locomotor activity, CPP magnitude, and reinstatement responses. Although females exhibited greater METH-induced locomotor activity than males, no significant sex differences were observed in CPP acquisition, reinstatement, or the behavioral effects of CD81 overexpression.
conclusionsReduced endogenous CD81 expression in the NAcc is associated with METH reward learning, whereas restoration of CD81 expression attenuates METH-induced locomotor, rewarding, and relapse-like behaviors. These findings identify CD81 as a previously unrecognized regulator of METH-induced neurobehavioral adaptations and support a role for accumbal CD81 in addiction-related neuroplasticity.
Indexed as
Identifiers
42734664What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.